To our knowledge, PLEASURABLE is the first study to explore a chemotherapy-sparing regimen incorporating dalpiciclib, pyrotinib, and endocrine therapy in the frontline treatment of ER-positive, HER2-positive ABC. The gene discussed is ESR1; the disease is aneurysmal bone cyst.